On the stock market since 2021, it operates in the world of health and science. It has 274 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 85% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $32.3M a year. A small number, but proof the product has real buyers.
There is $524.3M in the vault; even if every debt were paid off, $454.3M would remain.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
A loss of $198.7M against $32.3M in annual sales.
This stock swings about 2.2 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, VERV sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: VERV is a high-risk stock — not yet profitable, and its future rides on its product catching on.